Report scope. This 2026 Drug Asset Due Diligence Report evaluates Zervimesine as a potential licensing, partnership, acquisition, or option asset. The review separates verified evidence from open diligence questions across clinical development, intellectual property, market positioning, and transaction precedent.
Executive recommendation: CONDITIONAL GO
Zervimesine is a Small molecule drug associated with σ2 receptor and a global highest development stage of Phase 2. The lead disclosed indication is Lewy Body Disease. The current evidence supports a CONDITIONAL GO posture, subject to confirmation of study-level data, ownership, patent coverage, manufacturing readiness, and regional rights.
Decision memo
- Asset: Zervimesine
- Target: σ2 receptor
- Lead indication: Lewy Body Disease
- Highest phase: Phase 2
- Matched trials: 13
- Matched result records: 12
- Matched asset deals: 0
Use PatSnap Life Sciences MCP servers to validate the Zervimesine diligence evidence.
1. Asset identity and development status
The first diligence task is entity resolution. Teams should reconcile development codes, nonproprietary names, salts, formulations, combinations, sponsors, and predecessor owners before relying on portfolio counts. For Zervimesine, the MCP profile identifies σ2 receptor as the primary target context and Lewy Body Disease as the lead indication. Global phase labels are useful orientation points, but investment decisions require country- and indication-level status verification.
Confirm the exact molecule, formulation, route, dose, biomarker definition, and current sponsor. Review discontinuations separately from active development so that an historical high phase is not mistaken for a live program.
Use PatSnap Life Sciences MCP servers to validate the Zervimesine diligence evidence.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06961760 | Not Applicable | No longer available | Not disclosed | Not disclosed |
| NCT05893537 | Phase 2 | Terminated | Not disclosed | Not disclosed |
| NCT05531656 | Phase 2 | Active, not recruiting | Not disclosed | Not disclosed |
| NCT05248672 | Phase 1 | Completed | Not disclosed | Not disclosed |
| NCT05225415 | Phase 2 | Completed | Not disclosed | Not disclosed |
| NCT05225389 | Phase 1 | Completed | Not disclosed | Not disclosed |
| NCT04735536 | Phase 2 | Completed | Not disclosed | Not disclosed |
| NCT03716427 | Phase 1 | Completed | Not disclosed | Not disclosed |
| NCT03522129 | Phase 1 | Completed | Not disclosed | Not disclosed |
| NCT03507790 | Phase 2 | Completed | Not disclosed | Not disclosed |
| NCT03493282 | Phase 1/2 | Completed | Not disclosed | Not disclosed |
| NCT02907567 | Phase 1/2 | Completed | Not disclosed | Not disclosed |
| NCT02570997 | Phase 1 | Completed | Not disclosed | Not disclosed |
The clinical program should be audited for randomization, comparator relevance, dose selection, endpoint hierarchy, multiplicity, analysis population, geographic mix, and readout timing. Early-stage programs require attention to pharmacokinetics, pharmacodynamics, adverse events, dose-limiting toxicities, and the rationale for the expansion dose.
Use PatSnap Life Sciences MCP servers to validate the Zervimesine diligence evidence.
3. Clinical readouts: what is known
A Randomized, Double-blind, Placebo-controlled, Phase 2, 6-month Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies
Study: NCT05225415 (COG1201 SHIMMER | COG1201 | SHIMMER, CTgov). Phase: Phase 2. Enrollment: 130. Published: 2026-03-12.
Any Treatment Emergent Adverse Events (TEAE) = 42 Pts | Any Treatment Emergent Adverse Events (TEAE) = 40 Pts
ALZHEIMER’S DISEASE PIVOTAL TRIAL PHASE 2 MEETING WITH FDA
Study: NCT03507790 (SHINE, CTAD2025). Phase: Phase 2. Enrollment: 153. Published: 2025-12-01.
ADCS-ADL = 2.0 Point
Phase 2 study of zervimesine (CT1812) in participants with mild‐to‐moderate dementia with Lewy bodies (DLB)
Study: NCT05225415 (Pubmed | Alzheimers Dement). Phase: Phase 2. Enrollment: 109. Published: 2025-12-01.
ADCS-ADL(total score) = 4.0 Point ( 8.0) | AE(Discontinuation rates) = 16.3 %
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
Study: NCT03507790 (COG0201 | SHINE, CTgov). Phase: Phase 2. Enrollment: 153. Published: 2025-08-11.
All TEAEs = 36 Pts | All TEAEs = 42 Pts
Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s Disease
Study: NCT03507790 (COG0201 | SHINE, GlobeNewswire). Phase: Phase 2. Enrollment: 153. Published: 2025-07-29.
safety and tolerability = The SHINE study met its primary endpoint of safety and tolerability. Met | safety and tolerability = The SHINE study met its primary endpoint of safety and tolerability. Met
Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC
Study: NCT05225415 (COG1201 SHIMMER, GlobeNewswire). Phase: Phase 2. Enrollment: 130. Published: 2025-07-16.
NPI 12: Difference (%) = 86 | NPI 12: Difference (%) = 86
Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy
Study: NCT05893537 (MAGNIFY, Company_Website). Phase: Phase 2. Enrollment: 100. Published: 2025-05-08.
Growth velocity = -28.6 % | -
Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies
Study: NCT05225415 (SHIMMER, Company_Website). Phase: Phase 2. Enrollment: 130. Published: 2024-12-18.
Safety = Results indicate the study met its primary endpoint of safety and tolerability. Met | Safety = Results indicate the study met its primary endpoint of safety and tolerability. Met
Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD
Study: NCT03507790 (SHINE, GlobeNewswire). Phase: Phase 2. Enrollment: 153. Published: 2024-10-29.
ADAS-Cog = ADAS-Cog 11 scores showed 95% slowing of decline. | ADAS-Cog = ADAS-Cog 11 scores showed 95% slowing of decline.
LP057- PROTEOMIC ANALYSIS IN A PHASE 2 CLINICAL TRIAL STUDYING CT1812 TO IDENTIFY CSF AND PLASMA PHARMACODYNAMIC BIOMARKERS AND MOLECULAR CORRELATES OF EEG IN ALZHEIMER'S DISEASE PATIENTS
Study: NCT04735536 (CTAD2023). Phase: Phase 2. Enrollment: 16. Published: 2023-10-24.
Differentially abundant proteins(CSF proteins (p<0.05)) = 163.0 Protein
A Phase 1, Open-Label Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of a Single Oral Dose of [14C] CT1812 in Healthy Adult Male Subjects
Study: NCT05225389 (COG0108, CTgov). Phase: Phase 1. Enrollment: 8. Published: 2023-07-21.
Plasma CT1812 Concentration at 96 Hours Timepoint(Mean) = 0.0000707 μg/mL
Cognition Therapeutics Presents New Proteomic Data on Effect of CT1812 Treatment on Normalization of Disrupted Alzheimer’s Disease Processes
Study: NCT03493282 (SPARC, Corporate Publications). Phase: Phase 1/2. Enrollment: 23. Published: 2022-08-04.
TEAE(Serious) = SAE has not been reported. | TEAE(Serious) = SAE has not been reported.
For every reported endpoint, obtain the protocol, statistical analysis plan, patient disposition, baseline characteristics, subgroup definitions, exposure duration, and full safety tables. Conference abstracts and registry summaries can support screening, but they should not replace source data review in a binding transaction.
Use PatSnap Life Sciences MCP servers to validate the Zervimesine diligence evidence.
4. Market and competitive position
The commercial case depends on differentiated efficacy, tolerability, convenience, biomarker reach, treatment setting, and access. A target-level market may be attractive while an individual asset remains undifferentiated. Benchmark Zervimesine against approved therapies and clinical competitors in Lewy Body Disease, including likely standards of care at the expected launch date.
Build a scenario model around addressable patients, diagnosis and biomarker rates, line of therapy, duration, net price, uptake, displacement, combination costs, and probability-adjusted timelines. Test slower enrollment, delayed readout, narrower labels, safety restrictions, and competitor launches.
Use PatSnap Life Sciences MCP servers to validate the Zervimesine diligence evidence.
5. Transaction precedent and economics
| Date | Transaction | Status | Type | Disclosed value |
|---|---|---|---|---|
| No exact asset-specific transaction was returned. Use target-level precedents only as comparables and do not present them as asset transactions. | ||||
Transaction records should be normalized for territory, asset scope, phase at signing, option mechanics, development obligations, cost sharing, royalties, milestones, and change-of-control terms. Undisclosed economics must not be converted into invented benchmarks.
6. IP and freedom-to-operate screen
Complete a family-level patent review covering composition of matter, sequence or construct claims, polymorph and salt claims, formulation, dosing, combinations, biomarkers, manufacturing, and method of use. Verify priority, ownership, assignments, prosecution status, term adjustments, extensions, oppositions, and regional coverage. Freedom to operate is a separate legal analysis and should include competitor claims and platform dependencies.
The diligence room should reconcile inventorship, employee and contractor assignments, university or platform licenses, sublicensing restrictions, government rights, and obligations triggered by development milestones or commercialization.
Use PatSnap Life Sciences MCP servers to validate the Zervimesine diligence evidence.
7. Principal risks and diligence gates
- Identity risk: resolve all aliases, formulations, combinations, and owners.
- Clinical risk: confirm source data, protocol deviations, endpoint definitions, and safety follow-up.
- Regulatory risk: review agency correspondence, meeting minutes, holds, commitments, and indication-specific pathways.
- IP risk: validate enforceable coverage, remaining life, ownership, and freedom to operate.
- CMC risk: assess process control, analytical methods, comparability, scale-up, supply, and cost of goods.
- Commercial risk: pressure-test differentiation, market access, competitive timing, and realistic adoption.
- Transaction risk: map rights, encumbrances, royalties, options, consent requirements, and change-of-control provisions.
8. Final go/no-go memorandum
CONDITIONAL GO
Proceed only through staged diligence. Before exclusivity or a binding offer, require a verified asset identity package, complete clinical data room, regulatory correspondence, patent-family schedule, freedom-to-operate opinion, CMC package, ownership chain, regional rights map, and risk-adjusted valuation. Any material mismatch between public records and source documents should pause the process until reconciled.
Method note: This report uses PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP data retrieved on 2026-10-15. It is a screening and diligence framework, not medical, legal, regulatory, or investment advice.
